Stem definition | Drug id | CAS RN |
---|---|---|
angiotensin II receptor antagonists, antihypertensive (non-peptidic) | 1985 | 144689-63-4 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 2 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.02 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 26 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
April 25, 2002 | FDA | DAIICHI SANKYO |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malabsorption | 460.26 | 10.33 | 156 | 37710 | 3627 | 46644569 |
Sprue-like enteropathy | 452.12 | 10.33 | 98 | 37768 | 345 | 46647851 |
Intestinal villi atrophy | 147.54 | 10.33 | 33 | 37833 | 139 | 46648057 |
Acute kidney injury | 146.63 | 10.33 | 472 | 37394 | 235383 | 46412813 |
Hyperkalaemia | 100.04 | 10.33 | 161 | 37705 | 50548 | 46597648 |
Hyponatraemia | 98.64 | 10.33 | 239 | 37627 | 101093 | 46547103 |
Dehydration | 79.53 | 10.33 | 297 | 37569 | 159243 | 46488953 |
Blood pressure increased | 70.93 | 10.33 | 245 | 37621 | 126421 | 46521775 |
Renal failure | 59.52 | 10.33 | 215 | 37651 | 113379 | 46534817 |
Completed suicide | 56.18 | 10.33 | 24 | 37842 | 145896 | 46502300 |
Coeliac disease | 55.02 | 10.33 | 46 | 37820 | 7115 | 46641081 |
Hypertensive crisis | 54.33 | 10.33 | 61 | 37805 | 13554 | 46634642 |
Colitis microscopic | 54.32 | 10.33 | 44 | 37822 | 6512 | 46641684 |
Drug ineffective | 52.50 | 10.33 | 329 | 37537 | 677509 | 45970687 |
Hypertension | 51.42 | 10.33 | 303 | 37563 | 196053 | 46452143 |
Diarrhoea | 48.64 | 10.33 | 678 | 37188 | 558924 | 46089272 |
Dizziness | 47.81 | 10.33 | 453 | 37413 | 339961 | 46308235 |
Treatment failure | 45.34 | 10.33 | 10 | 37856 | 93077 | 46555119 |
Device related thrombosis | 44.04 | 10.33 | 21 | 37845 | 1206 | 46646990 |
Rheumatoid arthritis | 43.80 | 10.33 | 80 | 37786 | 240135 | 46408061 |
Bradycardia | 42.21 | 10.33 | 134 | 37732 | 66164 | 46582032 |
Death | 40.68 | 10.33 | 138 | 37728 | 335410 | 46312786 |
Blood urea increased | 40.09 | 10.33 | 73 | 37793 | 25279 | 46622917 |
Metabolic acidosis | 39.32 | 10.33 | 93 | 37773 | 38687 | 46609509 |
Toxicity to various agents | 37.29 | 10.33 | 72 | 37794 | 211694 | 46436502 |
Gallbladder polyp | 36.54 | 10.33 | 16 | 37850 | 753 | 46647443 |
Hypertensive emergency | 35.80 | 10.33 | 20 | 37846 | 1598 | 46646598 |
Pancreatic toxicity | 32.66 | 10.33 | 7 | 37859 | 23 | 46648173 |
Renal impairment | 32.55 | 10.33 | 133 | 37733 | 74239 | 46573957 |
Maternal exposure during pregnancy | 31.97 | 10.33 | 22 | 37844 | 102527 | 46545669 |
Cerebral infarction | 31.66 | 10.33 | 63 | 37803 | 23303 | 46624893 |
Syncope | 31.55 | 10.33 | 168 | 37698 | 104635 | 46543561 |
Blood pressure inadequately controlled | 31.18 | 10.33 | 27 | 37839 | 4379 | 46643817 |
Infusion related reaction | 31.17 | 10.33 | 22 | 37844 | 101186 | 46547010 |
Asthenia | 30.67 | 10.33 | 386 | 37480 | 310689 | 46337507 |
Synovitis | 28.86 | 10.33 | 7 | 37859 | 61068 | 46587128 |
Lower respiratory tract infection | 28.75 | 10.33 | 5 | 37861 | 55084 | 46593112 |
Exposure during pregnancy | 27.83 | 10.33 | 28 | 37838 | 108184 | 46540012 |
Weight decreased | 27.75 | 10.33 | 277 | 37589 | 210572 | 46437624 |
Pemphigus | 26.22 | 10.33 | 3 | 37863 | 45271 | 46602925 |
Blood pressure decreased | 25.63 | 10.33 | 103 | 37763 | 57056 | 46591140 |
Microvillous inclusion disease | 25.45 | 10.33 | 5 | 37861 | 9 | 46648187 |
Off label use | 25.00 | 10.33 | 193 | 37673 | 379648 | 46268548 |
Renal disorder | 24.91 | 10.33 | 62 | 37804 | 26624 | 46621572 |
Systemic lupus erythematosus | 24.62 | 10.33 | 11 | 37855 | 65169 | 46583027 |
Drug intolerance | 24.16 | 10.33 | 52 | 37814 | 146997 | 46501199 |
Therapeutic product effect decreased | 24.08 | 10.33 | 19 | 37847 | 82582 | 46565614 |
Blood creatinine increased | 24.03 | 10.33 | 124 | 37742 | 76279 | 46571917 |
Collagen disorder | 23.35 | 10.33 | 8 | 37858 | 192 | 46648004 |
Hypokalaemia | 23.09 | 10.33 | 136 | 37730 | 87888 | 46560308 |
Oligohydramnios | 22.69 | 10.33 | 25 | 37841 | 5440 | 46642756 |
Normocytic anaemia | 22.30 | 10.33 | 13 | 37853 | 1126 | 46647070 |
Product administration error | 21.93 | 10.33 | 49 | 37817 | 19632 | 46628564 |
Chronic kidney disease | 21.92 | 10.33 | 78 | 37788 | 40793 | 46607403 |
Anti-transglutaminase antibody increased | 21.70 | 10.33 | 4 | 37862 | 4 | 46648192 |
Normochromic anaemia | 21.48 | 10.33 | 8 | 37858 | 246 | 46647950 |
Decreased appetite | 21.46 | 10.33 | 246 | 37620 | 193590 | 46454606 |
Large intestine polyp | 21.31 | 10.33 | 29 | 37837 | 7832 | 46640364 |
Lymphocytic infiltration | 20.71 | 10.33 | 11 | 37855 | 795 | 46647401 |
Gastritis | 20.53 | 10.33 | 68 | 37798 | 34310 | 46613886 |
Hepatic function abnormal | 20.48 | 10.33 | 68 | 37798 | 34353 | 46613843 |
Enteritis | 19.97 | 10.33 | 26 | 37840 | 6729 | 46641467 |
Diverticulum | 19.95 | 10.33 | 34 | 37832 | 11172 | 46637024 |
Contraindicated product administered | 19.09 | 10.33 | 22 | 37844 | 79925 | 46568271 |
Gastrointestinal ischaemia | 18.80 | 10.33 | 7 | 37859 | 215 | 46647981 |
Hypoalbuminaemia | 18.39 | 10.33 | 31 | 37835 | 10096 | 46638100 |
Hypotension | 18.16 | 10.33 | 277 | 37589 | 232312 | 46415884 |
Angiosclerosis | 18.05 | 10.33 | 4 | 37862 | 16 | 46648180 |
Product substitution issue | 17.40 | 10.33 | 38 | 37828 | 14993 | 46633203 |
Liver disorder | 17.40 | 10.33 | 68 | 37798 | 37178 | 46611018 |
Spleen congestion | 17.17 | 10.33 | 6 | 37860 | 153 | 46648043 |
Product use issue | 16.79 | 10.33 | 32 | 37834 | 94612 | 46553584 |
Infection | 16.79 | 10.33 | 54 | 37812 | 133538 | 46514658 |
Burn oesophageal | 16.71 | 10.33 | 6 | 37860 | 166 | 46648030 |
Oedema peripheral | 15.61 | 10.33 | 198 | 37668 | 159508 | 46488688 |
Autoimmune enteropathy | 15.42 | 10.33 | 3 | 37863 | 5 | 46648191 |
Hyperuricaemia | 15.28 | 10.33 | 19 | 37847 | 4698 | 46643498 |
Gastrooesophageal reflux disease | 15.27 | 10.33 | 108 | 37758 | 74236 | 46573960 |
Therapeutic product effect incomplete | 15.15 | 10.33 | 25 | 37841 | 78128 | 46570068 |
Atrial tachycardia | 15.02 | 10.33 | 13 | 37853 | 2107 | 46646089 |
Gastritis erosive | 14.96 | 10.33 | 20 | 37846 | 5310 | 46642886 |
Haemorrhoids | 14.84 | 10.33 | 41 | 37825 | 18736 | 46629460 |
Hypoglycaemic coma | 14.73 | 10.33 | 14 | 37852 | 2560 | 46645636 |
Rhabdomyolysis | 14.58 | 10.33 | 70 | 37796 | 41839 | 46606357 |
Hospitalisation | 14.54 | 10.33 | 18 | 37848 | 63367 | 46584829 |
Aortic valve calcification | 14.39 | 10.33 | 7 | 37859 | 420 | 46647776 |
Febrile neutropenia | 14.29 | 10.33 | 35 | 37831 | 94592 | 46553604 |
Confabulation | 14.08 | 10.33 | 6 | 37860 | 264 | 46647932 |
Pain | 14.00 | 10.33 | 288 | 37578 | 476660 | 46171536 |
Leukocyturia | 13.91 | 10.33 | 9 | 37857 | 939 | 46647257 |
Aortic dissection | 13.86 | 10.33 | 11 | 37855 | 1581 | 46646615 |
Foetal exposure during pregnancy | 13.62 | 10.33 | 4 | 37862 | 30743 | 46617453 |
Wound | 13.58 | 10.33 | 9 | 37857 | 42793 | 46605403 |
Atrial fibrillation | 13.55 | 10.33 | 136 | 37730 | 103454 | 46544742 |
Hiatus hernia | 13.52 | 10.33 | 39 | 37827 | 18263 | 46629933 |
Hypocalcaemia | 13.41 | 10.33 | 50 | 37816 | 26735 | 46621461 |
Putamen haemorrhage | 13.33 | 10.33 | 5 | 37861 | 157 | 46648039 |
Device expulsion | 13.32 | 10.33 | 3 | 37863 | 27539 | 46620657 |
Azotaemia | 13.26 | 10.33 | 17 | 37849 | 4334 | 46643862 |
Heart rate irregular | 13.15 | 10.33 | 39 | 37827 | 18552 | 46629644 |
Oesophagitis | 13.04 | 10.33 | 32 | 37834 | 13619 | 46634577 |
Pregnancy | 13.04 | 10.33 | 3 | 37863 | 27134 | 46621062 |
Varicose vein | 12.99 | 10.33 | 17 | 37849 | 4421 | 46643775 |
Nail disorder | 12.81 | 10.33 | 23 | 37843 | 7873 | 46640323 |
Bezoar | 12.77 | 10.33 | 10 | 37856 | 1409 | 46646787 |
Prerenal failure | 12.66 | 10.33 | 10 | 37856 | 1427 | 46646769 |
Pneumonia | 12.64 | 10.33 | 222 | 37644 | 376098 | 46272098 |
Sopor | 12.54 | 10.33 | 40 | 37826 | 19788 | 46628408 |
Polyp | 12.49 | 10.33 | 18 | 37848 | 5125 | 46643071 |
Product use in unapproved indication | 12.40 | 10.33 | 35 | 37831 | 90238 | 46557958 |
Neutropenia | 12.32 | 10.33 | 67 | 37799 | 143137 | 46505059 |
Anuria | 12.22 | 10.33 | 28 | 37838 | 11403 | 46636793 |
Joint swelling | 12.04 | 10.33 | 82 | 37784 | 165991 | 46482205 |
Hepatorenal failure | 11.87 | 10.33 | 7 | 37859 | 619 | 46647577 |
Lymphocyte stimulation test positive | 11.83 | 10.33 | 7 | 37859 | 623 | 46647573 |
Purpura senile | 11.78 | 10.33 | 7 | 37859 | 628 | 46647568 |
Pharyngeal haematoma | 11.78 | 10.33 | 3 | 37863 | 24 | 46648172 |
Hair texture abnormal | 11.74 | 10.33 | 13 | 37853 | 2843 | 46645353 |
Anti-insulin antibody positive | 11.71 | 10.33 | 4 | 37862 | 95 | 46648101 |
Acquired oesophageal web | 11.55 | 10.33 | 5 | 37861 | 229 | 46647967 |
Skin exfoliation | 11.44 | 10.33 | 55 | 37811 | 32883 | 46615313 |
Hepatitis alcoholic | 11.23 | 10.33 | 4 | 37862 | 108 | 46648088 |
Anaemia | 11.19 | 10.33 | 279 | 37587 | 255500 | 46392696 |
Blood glucose increased | 11.15 | 10.33 | 98 | 37768 | 71915 | 46576281 |
Brain stem haemorrhage | 10.94 | 10.33 | 7 | 37859 | 716 | 46647480 |
Hypoperfusion | 10.78 | 10.33 | 9 | 37857 | 1388 | 46646808 |
Hyperlactacidaemia | 10.73 | 10.33 | 11 | 37855 | 2204 | 46645992 |
Musculoskeletal stiffness | 10.71 | 10.33 | 42 | 37824 | 97951 | 46550245 |
Intentional overdose | 10.63 | 10.33 | 23 | 37843 | 64921 | 46583275 |
Blood triglycerides increased | 10.60 | 10.33 | 27 | 37839 | 11756 | 46636440 |
Mucosa vesicle | 10.54 | 10.33 | 3 | 37863 | 38 | 46648158 |
Withdrawal hypertension | 10.33 | 10.33 | 4 | 37862 | 137 | 46648059 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malabsorption | 376.23 | 11.44 | 117 | 26371 | 1870 | 29924120 |
Sprue-like enteropathy | 354.39 | 11.44 | 78 | 26410 | 269 | 29925721 |
Intestinal villi atrophy | 86.79 | 11.44 | 21 | 26467 | 120 | 29925870 |
Gastrointestinal disorder | 77.03 | 11.44 | 109 | 26379 | 28028 | 29897962 |
Blood pressure increased | 68.00 | 11.44 | 177 | 26311 | 71751 | 29854239 |
Coeliac disease | 64.05 | 11.44 | 23 | 26465 | 582 | 29925408 |
Cerebral infarction | 61.84 | 11.44 | 95 | 26393 | 26278 | 29899712 |
Renal impairment | 60.85 | 11.44 | 188 | 26300 | 83996 | 29841994 |
Death | 58.58 | 11.44 | 145 | 26343 | 357138 | 29568852 |
Hepatic function abnormal | 56.94 | 11.44 | 119 | 26369 | 41826 | 29884164 |
Toxicity to various agents | 53.32 | 11.44 | 47 | 26441 | 177136 | 29748854 |
Hyperkalaemia | 49.15 | 11.44 | 149 | 26339 | 65861 | 29860129 |
Interstitial lung disease | 47.78 | 11.44 | 139 | 26349 | 60058 | 29865932 |
Blood pressure decreased | 46.68 | 11.44 | 118 | 26370 | 46957 | 29879033 |
Hyperuricaemia | 46.45 | 11.44 | 44 | 26444 | 7350 | 29918640 |
Hypertension | 45.48 | 11.44 | 220 | 26268 | 121134 | 29804856 |
Colitis microscopic | 38.51 | 11.44 | 22 | 26466 | 1681 | 29924309 |
Syncope | 37.81 | 11.44 | 162 | 26326 | 84741 | 29841249 |
Diarrhoea | 37.40 | 11.44 | 455 | 26033 | 333648 | 29592342 |
Loss of consciousness | 33.46 | 11.44 | 149 | 26339 | 79226 | 29846764 |
Intestinal intraepithelial lymphocytes increased | 32.56 | 11.44 | 6 | 26482 | 5 | 29925985 |
Completed suicide | 31.60 | 11.44 | 25 | 26463 | 99467 | 29826523 |
Dermatitis infected | 31.22 | 11.44 | 9 | 26479 | 109 | 29925881 |
Dehydration | 30.34 | 11.44 | 200 | 26288 | 123339 | 29802651 |
Dizziness | 28.93 | 11.44 | 281 | 26207 | 194628 | 29731362 |
Gastrointestinal erosion | 28.23 | 11.44 | 11 | 26477 | 351 | 29925639 |
Microvillous inclusion disease | 27.83 | 11.44 | 7 | 26481 | 48 | 29925942 |
Hypotension | 27.28 | 11.44 | 284 | 26204 | 200281 | 29725709 |
Product use in unapproved indication | 26.75 | 11.44 | 16 | 26472 | 73677 | 29852313 |
Lymphangiectasia intestinal | 26.70 | 11.44 | 5 | 26483 | 5 | 29925985 |
Pancreatic neoplasm | 26.11 | 11.44 | 14 | 26474 | 945 | 29925045 |
Hospitalisation | 26.09 | 11.44 | 4 | 26484 | 44315 | 29881675 |
Acute kidney injury | 25.97 | 11.44 | 362 | 26126 | 273480 | 29652510 |
Hyperkinetic heart syndrome | 25.94 | 11.44 | 8 | 26480 | 124 | 29925866 |
Hypertensive crisis | 25.29 | 11.44 | 34 | 26454 | 8323 | 29917667 |
Off label use | 25.28 | 11.44 | 124 | 26364 | 249166 | 29676824 |
Weight decreased | 23.56 | 11.44 | 220 | 26268 | 150701 | 29775289 |
Neutropenia | 23.52 | 11.44 | 49 | 26439 | 128491 | 29797499 |
Liver disorder | 22.95 | 11.44 | 68 | 26420 | 29654 | 29896336 |
Atrophy | 22.39 | 11.44 | 13 | 26475 | 1024 | 29924966 |
Renal disorder | 22.20 | 11.44 | 58 | 26430 | 23526 | 29902464 |
Palmar-plantar erythrodysaesthesia syndrome | 19.94 | 11.44 | 42 | 26446 | 14828 | 29911162 |
Hypokalaemia | 19.48 | 11.44 | 92 | 26396 | 50100 | 29875890 |
Transient aphasia | 18.32 | 11.44 | 6 | 26482 | 114 | 29925876 |
Renal failure | 18.15 | 11.44 | 184 | 26304 | 128782 | 29797208 |
Enterocolitis viral | 18.12 | 11.44 | 5 | 26483 | 51 | 29925939 |
Tropical sprue | 18.10 | 11.44 | 3 | 26485 | 0 | 29925990 |
Borderline personality disorder | 17.60 | 11.44 | 8 | 26480 | 377 | 29925613 |
Plasma cell myeloma | 17.52 | 11.44 | 13 | 26475 | 53449 | 29872541 |
Blood pressure inadequately controlled | 17.50 | 11.44 | 16 | 26472 | 2554 | 29923436 |
Product administration error | 17.44 | 11.44 | 39 | 26449 | 14338 | 29911652 |
Chronic kidney disease | 17.44 | 11.44 | 73 | 26415 | 37765 | 29888225 |
Immune-mediated myositis | 17.42 | 11.44 | 12 | 26476 | 1273 | 29924717 |
Gastrooesophageal reflux disease | 17.09 | 11.44 | 65 | 26423 | 32190 | 29893800 |
Pulmonary hypoplasia | 16.73 | 11.44 | 8 | 26480 | 423 | 29925567 |
Anaplastic astrocytoma | 16.45 | 11.44 | 6 | 26482 | 159 | 29925831 |
Drug abuse | 16.11 | 11.44 | 30 | 26458 | 82042 | 29843948 |
Autoimmune enteropathy | 16.09 | 11.44 | 4 | 26484 | 26 | 29925964 |
Cerebral haemorrhage | 15.59 | 11.44 | 64 | 26424 | 32823 | 29893167 |
Drug ineffective | 15.56 | 11.44 | 210 | 26278 | 340177 | 29585813 |
Large intestine polyp | 15.48 | 11.44 | 24 | 26464 | 6685 | 29919305 |
Prerenal failure | 15.46 | 11.44 | 13 | 26475 | 1858 | 29924132 |
Sinus node dysfunction | 15.41 | 11.44 | 18 | 26470 | 3825 | 29922165 |
Colon cancer | 15.35 | 11.44 | 27 | 26461 | 8345 | 29917645 |
Anaemia | 15.10 | 11.44 | 263 | 26225 | 207729 | 29718261 |
Gastroenteritis | 15.00 | 11.44 | 35 | 26453 | 13231 | 29912759 |
Treatment failure | 14.89 | 11.44 | 6 | 26482 | 34673 | 29891317 |
Haemorrhoids | 14.80 | 11.44 | 33 | 26455 | 12108 | 29913882 |
Febrile neutropenia | 14.64 | 11.44 | 47 | 26441 | 106646 | 29819344 |
Hypoalbuminaemia | 14.49 | 11.44 | 31 | 26457 | 11061 | 29914929 |
Decreased appetite | 14.49 | 11.44 | 199 | 26289 | 149711 | 29776279 |
Peripheral venous disease | 14.44 | 11.44 | 13 | 26475 | 2035 | 29923955 |
Product odour abnormal | 14.24 | 11.44 | 8 | 26480 | 592 | 29925398 |
Collagen disorder | 14.21 | 11.44 | 5 | 26483 | 119 | 29925871 |
Hypertensive emergency | 14.16 | 11.44 | 9 | 26479 | 835 | 29925155 |
Tinea pedis | 13.91 | 11.44 | 10 | 26478 | 1136 | 29924854 |
Renal cyst haemorrhage | 13.35 | 11.44 | 5 | 26483 | 143 | 29925847 |
Gastric cancer | 13.27 | 11.44 | 19 | 26469 | 4931 | 29921059 |
Oligohydramnios | 12.79 | 11.44 | 6 | 26482 | 304 | 29925686 |
Echocardiogram abnormal | 12.76 | 11.44 | 8 | 26480 | 724 | 29925266 |
Helicobacter test positive | 12.73 | 11.44 | 7 | 26481 | 497 | 29925493 |
Peripheral arterial occlusive disease | 12.65 | 11.44 | 19 | 26469 | 5149 | 29920841 |
Intestinal ulcer perforation | 12.57 | 11.44 | 3 | 26485 | 16 | 29925974 |
Blood creatinine increased | 12.19 | 11.44 | 129 | 26359 | 91246 | 29834744 |
Gastrointestinal mucosa hyperaemia | 12.16 | 11.44 | 5 | 26483 | 184 | 29925806 |
Pancytopenia | 11.99 | 11.44 | 37 | 26451 | 85015 | 29840975 |
Blood creatine phosphokinase abnormal | 11.94 | 11.44 | 5 | 26483 | 193 | 29925797 |
Rectal ulcer haemorrhage | 11.84 | 11.44 | 4 | 26484 | 84 | 29925906 |
Diabetic nephropathy | 11.50 | 11.44 | 11 | 26477 | 1858 | 29924132 |
Atrioventricular block | 11.47 | 11.44 | 22 | 26466 | 7260 | 29918730 |
Source | Code | Description |
---|---|---|
ATC | C09CA08 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain |
ATC | C09DA08 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics |
ATC | C09DB02 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers |
ATC | C09DX03 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations |
MeSH PA | D047228 | Angiotensin II Type 1 Receptor Blockers |
MeSH PA | D057911 | Angiotensin Receptor Antagonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
FDA MoA | N0000000070 | Angiotensin 2 Receptor Antagonists |
FDA EPC | N0000175561 | Angiotensin 2 Receptor Blocker |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:61016 | angiotensin receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Chronic heart failure | off-label use | 48447003 | |
Atrial fibrillation | off-label use | 49436004 | DOID:0060224 |
Diastolic heart failure | off-label use | 418304008 | DOID:9775 |
Nondiabetic Proteinuric Nephropathy | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperkalemia | contraindication | 14140009 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Angioedema | contraindication | 41291007 | DOID:1558 |
Hypokalemia | contraindication | 43339004 | |
Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
Low blood pressure | contraindication | 45007003 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Chronic idiopathic constipation | contraindication | 82934008 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hypomagnesemia | contraindication | 190855004 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Pregnancy, function | contraindication | 289908002 | |
Renal artery stenosis | contraindication | 302233006 | |
Azotemia | contraindication | 445009001 | |
Severe Aortic Valve Stenosis | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.25 | acidic |
pKa2 | 5.76 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Type-1 angiotensin II receptor | GPCR | ANTAGONIST | IC50 | 8.10 | IUPHAR | CHEMBL | |||
Type-1 angiotensin II receptor | GPCR | IC50 | 8.09 | CHEMBL |
ID | Source |
---|---|
4021345 | VUID |
N0000179505 | NUI |
D01204 | KEGG_DRUG |
144689-24-7 | SECONDARY_CAS_RN |
4021344 | VANDF |
4021345 | VANDF |
C0386394 | UMLSCUI |
C1098320 | UMLSCUI |
CHEBI:31932 | CHEBI |
CHEBI:48416 | CHEBI |
OLM | PDB_CHEM_ID |
CHEMBL1200692 | ChEMBL_ID |
CHEMBL1516 | ChEMBL_ID |
D000068557 | MESH_DESCRIPTOR_UI |
130881 | PUBCHEM_CID |
C437965 | MESH_SUPPLEMENTAL_RECORD_UI |
7787 | INN_ID |
8612 | INN_ID |
6M97XTV3HD | UNII |
8W1IQP3U10 | UNII |
158781 | PUBCHEM_CID |
591 | IUPHAR_LIGAND_ID |
DB00275 | DRUGBANK_ID |
118463 | RXNORM |
16642 | MMSL |
245076 | MMSL |
d04801 | MMSL |
009634 | NDDF |
009635 | NDDF |
385540001 | SNOMEDCT_US |
412259001 | SNOMEDCT_US |
412260006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5002 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5003 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5004 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5005 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5006 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-248 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-249 | TABLET | 20 mg | ORAL | ANDA | 21 sections |
Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-250 | TABLET | 40 mg | ORAL | ANDA | 21 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-251 | TABLET | 20 mg | ORAL | ANDA | 20 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-252 | TABLET | 40 mg | ORAL | ANDA | 20 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-253 | TABLET | 40 mg | ORAL | ANDA | 20 sections |
Amlodipine and Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-311 | TABLET | 40 mg | ORAL | ANDA | 21 sections |
Amlodipine and Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-312 | TABLET | 20 mg | ORAL | ANDA | 21 sections |
Amlodipine and Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-313 | TABLET | 40 mg | ORAL | ANDA | 21 sections |
Amlodipine and Olmesartan Medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13668-324 | TABLET | 20 mg | ORAL | ANDA | 21 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/25 mg | HUMAN PRESCRIPTION DRUG LABEL | 3 | 13668-382 | TABLET | 40 mg | ORAL | ANDA | 25 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/12.5 mg | HUMAN PRESCRIPTION DRUG LABEL | 3 | 13668-383 | TABLET | 40 mg | ORAL | ANDA | 25 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/25 mg | HUMAN PRESCRIPTION DRUG LABEL | 3 | 13668-385 | TABLET | 40 mg | ORAL | ANDA | 25 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/12.5 mg | HUMAN PRESCRIPTION DRUG LABEL | 3 | 13668-386 | TABLET | 40 mg | ORAL | ANDA | 25 sections |
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20/5/12.5 mg | HUMAN PRESCRIPTION DRUG LABEL | 3 | 13668-397 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
olmesartan medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-320 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
olmesartan medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-321 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 27 sections |
olmesartan medoxomil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-322 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 27 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16729-366 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16729-367 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16729-368 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 26 sections |
Amlodipine besylate and Olmesartan medoxomil | Human Prescription Drug Label | 2 | 27241-083 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
Amlodipine besylate and Olmesartan medoxomil | Human Prescription Drug Label | 2 | 27241-084 | TABLET | 40 mg | ORAL | ANDA | 26 sections |
Amlodipine besylate and Olmesartan medoxomil | Human Prescription Drug Label | 2 | 27241-085 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
Amlodipine besylate and Olmesartan medoxomil | Human Prescription Drug Label | 2 | 27241-086 | TABLET | 40 mg | ORAL | ANDA | 26 sections |